Amylyx Pharmaceuticals, Inc. (AMLX) Stock Grade

About Amylyx Pharmaceuticals, Inc.'s fundamentals

Amylyx Pharmaceuticals is a biotechnology company with a market capitalization of $3.3 billion that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of 0.0%. The company experienced a complete decline in revenue year-over-year, contracting by 100.0%, indicating a significant disruption to its business operations. The company does not pay dividends and traditional valuation metrics like P/E ratio and return on equity are not meaningful given the current financial position.